Download PDF
Der Klinikarzt 2017; 46(10): 476-483
DOI: 10.1055/s-0043-120235
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Medikamentöse Therapie der Herzinsuffizienz

Neues zu Guidelines
Dominik Berliner
,
Johann Bauersachs
Further Information

Publication History

Publication Date:
24 October 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die chronische Herzinsuffizienz nimmt aufgrund einer veränderten Altersstruktur der Bevölkerung, aber auch einer verbesserten medizinischen (Akut-)Versorgung kardiovaskulärer Erkrankungen an Inzidenz und Prävalenz zu. Unbehandelt hat sie eine schlechte Prognose – (rezidivierende) Hospitalisierungen stellen ein zunehmendes gesundheitsökonomisches Problem dar. Fortschritte in der Therapie der Patienten durch moderne Substanzen und konsequente Umsetzung der Therapieempfehlungen können die Prognose der Betroffenen deutlich verbessern. Neben der Etablierung der Mineralokortikoid-Rezeptor-Antagonisten bereits in milderen Stadien der systolischen Herzinsuffizienz und der Therapie mit dem If-Kanal-Blocker Ivabradin verspricht insbesondere der neue Angiotensin-Rezeptor-/Neprilysin-Inhibitor Sacubitril/Valsartan eine Verbesserung der Prognose. Daneben rücken zunehmend Diagnostik und Therapie prognosemodifizierender Komorbiditäten weiter in den Fokus. Die im Sommer 2016 vorgestellten aktualisierten Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) fassen den aktuellen Stand der Evidenz zusammen und geben Empfehlungen zur zeitgemäßen Therapie der Herzinsuffizienz.

 

  • Literatur

  • 1 Lindenfeld J, Albert NM, Boehmer JP. et al. for the Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16 e1–194
    PubMedGoogle Scholar
  • 2 Askoxylakis V, Thieke C, Pleger ST. et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010; 10: 105
    CrossrefPubMedGoogle Scholar
  • 3 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200
    CrossrefPubMedGoogle Scholar
  • 4 Yancy CW, Jessup M, Bozkurt B. et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 68: 1476-1488
    CrossrefPubMedGoogle Scholar
  • 5 CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
    CrossrefPubMedGoogle Scholar
  • 6 SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
    CrossrefPubMedGoogle Scholar
  • 7 Packer M, Poole-Wilson PA, Armstrong PW. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318
    CrossrefPubMedGoogle Scholar
  • 8 CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
    CrossrefPubMedGoogle Scholar
  • 9 Hjalmarson A, Goldstein S, Fagerberg B. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-1302
    CrossrefPubMedGoogle Scholar
  • 10 Flather MD, Shibata MC, Coats AJ. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225
    CrossrefPubMedGoogle Scholar
  • 11 Pitt B, Zannad F, Remme WJ. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
    CrossrefPubMedGoogle Scholar
  • 12 Zannad F, McMurray JJ, Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
    CrossrefPubMedGoogle Scholar
  • 13 Berliner D, Bauersachs J. Herzinsuffizienz im Alter. Geriatrie-Report 2012; 7: 16-18
    PubMedGoogle Scholar
  • 14 Eschalier R, McMurray JJ, Swedberg K. et al. EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-1593
    CrossrefPubMedGoogle Scholar
  • 15 Swedberg K, Komajda M, Bohm M. et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
    CrossrefPubMedGoogle Scholar
  • 16 Berliner D, Bauersachs J. Eine vielversprechende neue Behandlungsoption – Verändert LCZ696 die Therapie der Herzinsuffizienz?. Kompendium Herz-Kreislauf 2015; 11: 23-27
    PubMedGoogle Scholar
  • 17 McMurray JJ, Packer M, Desai AS. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004
    CrossrefPubMedGoogle Scholar
  • 18 Kristensen SL, Preiss D, Jhund PS. et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9 e0025602016
    PubMedGoogle Scholar
  • 19 Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533
    CrossrefPubMedGoogle Scholar
  • 20 Adams KF, Butler J, Patterson JH. et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 2016; 18: 1072-1081
    CrossrefPubMedGoogle Scholar
  • 21 Gheorghiade M, Patel K, Filippatos G. et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013; 15: 551-559
    CrossrefPubMedGoogle Scholar
  • 22 Bavendiek U, Aguirre Davila L, Koch A. et al. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J. 2017 Jan 8: ehw577 [Epub ahead of print]
    PubMedGoogle Scholar
  • 23 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    CrossrefPubMedGoogle Scholar
  • 24 Anker SD, Comin Colet J, Filippatos G. et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
    CrossrefPubMedGoogle Scholar